Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Weighted Average) (2022 - 2025)

Entrada Therapeutics has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $41.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $41.4 million for Q4 2025, up 10.9% from a year ago — trailing twelve months through Dec 2025 was $41.4 million (up 10.9% YoY), and the annual figure for FY2025 was $41.4 million, up 10.9%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $41.4 million at Entrada Therapeutics, roughly flat from $41.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TRDA hit a ceiling of $41.5 million in Q3 2025 and a floor of $31.2 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $33.3 million (2023), compared with a mean of $35.4 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 23.33% in 2024, while the deepest fall reached 2.04% in 2024.
  • Entrada Therapeutics' Shares Outstanding (Weighted Average) stood at $31.3 million in 2022, then grew by 5.61% to $33.1 million in 2023, then grew by 12.88% to $37.3 million in 2024, then rose by 10.9% to $41.4 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $41.4 million (Q4 2025), $41.5 million (Q3 2025), and $41.2 million (Q2 2025) per Business Quant data.